Live Breaking News & Updates on Antlera Therapeutics

Stay updated with breaking news from Antlera therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Researchers develop antibody drug that could treat diabetic retinopathy


Date Time
Researchers develop antibody drug that could treat diabetic retinopathy
The life-saving diabetic medication insulin, developed at the University of Toronto 100 years ago, was the first biologic therapy – a protein to treat disease. Now, a new biologic therapy developed by U of T researchers has potential to reverse a common diabetes complication.
A team led by Stéphane Angers, professor and associate dean of research at the Leslie Dan Faculty of Pharmacy, has developed a synthetic antibody as a promising treatment for diabetic retinopathy, which causes blindness and affects about 30 per cent of diabetes patients.
“This study has shown that these antibodies are very attractive therapeutics to restore blood-retina barrier defects,” said Rony Chidiac, a post-doctoral researcher in the Angers lab and lead author of the study. ....

Sachdev Sidhu , Harald Junge , Steve Southon , Rony Chidiac , University Of Toronto , University Of Minnesota , Donnelly Centre For Cellular , Canadian Institutes Of Health Research , Biomolecular Research , Leslie Dan Faculty , Donnelly Centre , Antlera Therapeutics , Canadian Institutes , Health Research , University Of Minnesota , Regenerative Medicine , Diabetic Retinopathy , Macular Degeneration , Agenetic Mutation , Blood Vessels , Eye Damage , சச்ச்தேவ் ஸிட்ஹு , பல்கலைக்கழகம் ஆஃப் டொராண்டோ , பல்கலைக்கழகம் ஆஃப் மினசோட்டா , டோநிலீ மையம் க்கு செல்லுலார் , கனடியன் நிறுவனங்கள் ஆஃப் ஆரோக்கியம் ஆராய்ச்சி ,

U of T researchers develop antibody drug that could treat diabetic retinopathy


Pharmacy
U of T researchers develop antibody drug that could treat diabetic retinopathy
A team led by U of T researcher Stéphane Angers has developed a synthetic antibody as a promising treatment for diabetic retinopathy, which causes blindness and affects about one third of diabetes patients (photo by Tetra Images via Getty Images)
The life-saving diabetic medication insulin, developed at the University of Toronto 100 years ago, was the first biologic therapy – a protein to treat disease. Now, a new biologic therapy developed by U of T researchers has potential to reverse a common diabetes complication.
A team led by  ....

Sachdev Sidhu , Harald Junge , Steve Southon , Rony Chidiac , University Of Toronto , University Of Minnesota , Donnelly Centre For Cellular , Canadian Institutes Of Health Research , Biomolecular Research , Leslie Dan Faculty , Donnelly Centre , Antlera Therapeutics , Canadian Institutes , Health Research , சச்ச்தேவ் ஸிட்ஹு , பல்கலைக்கழகம் ஆஃப் டொராண்டோ , பல்கலைக்கழகம் ஆஃப் மினசோட்டா , டோநிலீ மையம் க்கு செல்லுலார் , கனடியன் நிறுவனங்கள் ஆஃப் ஆரோக்கியம் ஆராய்ச்சி , உயிர் மூலக்கூறு ஆராய்ச்சி , லெஸ்லி டான் ஆசிரிய , டோநிலீ மையம் , கனடியன் நிறுவனங்கள் , ஆரோக்கியம் ஆராய்ச்சி ,